U.S. Law Firm, Kenneth B. Moll & Associates, Ltd., Filed First Class Action Lawsuit on Behalf of All Canadian Consumers of Vioxx

CHICAGO--(CCNMatthews - Sep 12, 2005) -

On September 12, 2005, the law firm of KENNETH B. MOLL & ASSOCIATES, LTD. filed the first class action lawsuit on behalf of all citizens of Canada who allegedly died or were seriously injured by the pain medication Vioxx. The suit accuses United States pharmaceutical giant Merck & Co. of failing to properly research the known risks of Vioxx and warn Canadian consumers of potentially fatal side effects. "Vioxx should never have been marketed in the first place," said Kenneth B. Moll, whose firm filed the first worldwide class action regarding Vioxx last fall.

On September 30, 2004, Merck withdrew Vioxx from all worldwide markets after studies showed a three-fold risk of heart attack and stroke. "Merck's decision to withdraw Vioxx from the market came years after the company first learned of the health risks," said Mr. Moll. "Countless individuals in Canada and around the world have suffered severe and fatal injuries which could have been avoided if Merck had acted responsibly." On August 19, 2005, a Texas jury awarded $253.5 million to a widow of a man who died after taking Vioxx. "The verdict clearly shows Merck's culpability in their decision to put profits ahead of the safety of their consumers," said Mr. Moll.

KENNETH B. MOLL & ASSOCIATES, LTD., one of the premier class action and mass tort law firms in the U.S.A., has been contacted by thousands of people in over 57 countries worldwide who have taken Vioxx. "This is the first class action lawsuit filed on behalf of all Canadian consumers to seek compensation for serious injuries and deaths caused by a dangerous drug," said Mr. Moll. Previously, Kenneth B. Moll & Associates, Ltd. filed the first class action lawsuit against Merck, on behalf of all citizens of Italy, England, France and Australia.

A copy of the filed complaint may be found on our website at www.kbmoll.com.

Mr. Moll will be available for interviews in Toronto on September 13th and 14th.